ZimultiAcompliaReport
Your INDEPENDENT source of news about diet drug Acomplia / Zimulti (Rimonabant)  
What Doctors Say About Acomplia / Zimulti
 

Here are some of the things being said about Acomplia by doctors. Keep in mind that some of these may have an interest in the clinical trials underway sponsored by Sanofi-Aventis.


"If there was a pill available that was safe, effective and made it easy to lose any weight at all, there would be a truly massive market."

Dr. Steve Bloom, researcher at Imperial College in London, quoted on June 28, 2006 by Bloomberg


"Acomplia's been given to 13,000 people but you just don't completely know what happens when you give it to a million.''

Dr. Louis J. Aronne, New York Hospital - Cornell Medical Center, quoted on June 28, 2006 by Bloomberg


"Lifestyle interventions including exercise, behavior modification and reduced caloric intake should be mainstays in the battle against obesity. Unfortunately, there is no quick fix."

Dr. JoAnne Foody, cardiologist at Yale University in New Haven, Connecticut, quoted on June 28, 2006 by Bloomberg.


"It will be very widely prescribed if found safe and effective in the remaining trials that are due to come out over the next year or two."

Dr.Christopher Cannon, a cardiologist at Brigham and Women's Hospital in Boston and an associate professor of medicine at Harvard University, quoted on Aug. 29. 2004 by Bloomberg.


"Rimonabant shows a substantial weight reduction, and if that's possible without side effects it could be promising. I have concerns about the idea you just buy a drug and that's it, buying weight reduction instead of changing lifestyle habits.''

Dr.Otto Smiseth, a professor of medicine at University of Oslo, quoted on Aug. 29. 2004 by Bloomberg.


"We come up with new drugs on the drawing board all the time, but rarely do they work the way we think they will. This one did. I think the drug has incredible potential."

Dr. Elbert Glover of West Virginia University Medical School quoted in the Aug. 14, 2004 issue of Newsweek.

 

Privacy Policy | Terms and Disclaimers | About the Zimulti Acomplia Report
Click to VerifyWe subscribe to the HONcode principles of the HON Foundation.

This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Aventis Inc., which is marketing it in Europe under the trademarked name Acomplia and in the United States under the trademarked name Zimulti.. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.

(c) 2004-2006 Medical Week News, Inc. All Rights Reserved

Last Updated: 05/08/2007